BACKGROUND
Overriding the differentiation blockage in acute myeloid
leukemia (AML) is the most successful mode-of-action in
leukemia therapy - now curing the vast majority of patients with acute promyelocytic
leukemia (APL) using all-trans retinoic acid (ATRA)-based regimens.